Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul-Aug;5(4):1040-1049.e4.
doi: 10.1016/j.jaip.2016.11.026. Epub 2017 Jan 18.

Real-Life Outcomes for Patients with Asthma Prescribed Spacers for Use with Either Extrafine- or Fine-Particle Inhaled Corticosteroids

Affiliations

Real-Life Outcomes for Patients with Asthma Prescribed Spacers for Use with Either Extrafine- or Fine-Particle Inhaled Corticosteroids

Theresa W Guilbert et al. J Allergy Clin Immunol Pract. 2017 Jul-Aug.

Abstract

Background: Spacers are often used with pressurized metered-dose inhalers (pMDIs) to eliminate the need for coordinating inhalation with actuation.

Objective: To investigate the real-life effectiveness of spacers prescribed for use with either extrafine- or fine-particle inhaled corticosteroids (ICSs).

Methods: This historical matched cohort study examined anonymous medical record data over 2 years (1-year baseline, 1-year outcome) for patients with asthma aged 12 to 80 years initiating ICSs by pMDI with or without prescribed spacer. We compared outcomes for spacer versus no-spacer arms, matched for key baseline and asthma-related characteristics, within 2 ICS cohorts: (1) extrafine-particle ICS (beclomethasone) and (2) fine-particle ICS (fluticasone). Effectiveness end points were compared using conditional regression methods.

Results: Matched spacer and no-spacer arms of the extrafine-particle ICS cohort each included 2090 patients (69% females; median age, 46-47 years) and the 2 arms of the fine-particle ICS cohort each included 444 patients (67% females; median age, 45 years). With extrafine-particle ICS, we observed no significant difference between spacer and no-spacer arms in severe exacerbation rate (primary end point): adjusted rate ratio, 1.01 (95% CI, 0.83-1.23). With fine-particle ICS, the severe exacerbation rate ratio with spacers was 0.77 (0.47-1.25). Oropharyngeal candidiasis incidence was low and similar in spacer and no-spacer arms for both ICS cohorts.

Conclusions: We found no evidence that prescribed spacer devices are associated with improved asthma outcomes for extrafine- or fine-particle ICS administered by pMDI. These findings challenge long-standing assumptions that spacers should improve pMDI effectiveness and indicate the need for pragmatic trials of spacers in clinical practice.

Keywords: Asthma; Inhaled corticosteroid; Particle size; Pressurized metered-dose inhaler; Spacer device.

PubMed Disclaimer

Comment in

  • Impact of Spacers on Therapeutic Ratio with Inhaled Corticosteroids.
    Lipworth B, Jabbal S. Lipworth B, et al. J Allergy Clin Immunol Pract. 2017 Jul-Aug;5(4):1163. doi: 10.1016/j.jaip.2017.03.011. J Allergy Clin Immunol Pract. 2017. PMID: 28689833 No abstract available.
  • Reply.
    Guilbert TW, Price DB. Guilbert TW, et al. J Allergy Clin Immunol Pract. 2017 Jul-Aug;5(4):1163-1164. doi: 10.1016/j.jaip.2017.03.010. J Allergy Clin Immunol Pract. 2017. PMID: 28689834 No abstract available.

MeSH terms

Substances